Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial
Introduction: Efforts to control the COVID-19 pandemic are still on. This study aimed to evaluate the effect of sofosbuvir on length of hospital stay and complications in COVID-19 cases with moderate severity. Methods: This randomized clinical trial was done on moderate COVID-19 cases, who were...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shahid Beheshti University of Medical Sciences
2022-06-01
|
| Series: | Archives of Academic Emergency Medicine |
| Subjects: | |
| Online Access: | https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/1621 |
| _version_ | 1828327321212289024 |
|---|---|
| author | Rama Bozorgmehr Farbod Amiri Mohammad Hosein Zade Fariba Ghorbani Arash Khameneh Bagheri Esmat Yazdi Sayyed Mojtaba Nekooghadam Guitti Pourdowlat Alireza Fatemi |
| author_facet | Rama Bozorgmehr Farbod Amiri Mohammad Hosein Zade Fariba Ghorbani Arash Khameneh Bagheri Esmat Yazdi Sayyed Mojtaba Nekooghadam Guitti Pourdowlat Alireza Fatemi |
| author_sort | Rama Bozorgmehr |
| collection | DOAJ |
| description |
Introduction: Efforts to control the COVID-19 pandemic are still on. This study aimed to evaluate the effect of sofosbuvir on length of hospital stay and complications in COVID-19 cases with moderate severity.
Methods: This randomized clinical trial was done on moderate COVID-19 cases, who were admitted to Shohadaye Tajrish Hospital, Tehran, Iran, from 4/2021 to 9/2021. Eligible patients were randomly allocated into two groups of intervention (sofosbuvir) and control, and their outcomes were compared regarding the length of hospital stay and complications.
Results: 100 COVID-19 cases were randomly divided into two groups of 50 patients, as the intervention and control groups. The mean age of patients was 50.56 ± 12.23 and 57.1±14.1 years in the intervention and control groups, respectively (p = 0.02). The two groups were similar regarding distribution of gender (p = 0.15), underlying diseases (p = 0.08), the severity of COVID-19 (p = 0.80) at the time of admission, signs and symptoms (p > 0.05), and essential laboratory profile (p > 0.05). The length of hospital stay in the control and intervention groups was 7.7 ± 4.09 days and 4.7±1.6 days, respectively (p = 0.02). None of our patients needed ICU or mechanical ventilation.
Conclusion: Sofosbuvir may decrease the length of hospital stay of COVID-19 cases with moderate severity, without a significant effect on the rate of intensive care unit (ICU) need and mortality.
|
| first_indexed | 2024-04-13T19:53:51Z |
| format | Article |
| id | doaj.art-6bba935b0c48471aa4742517961a3f6f |
| institution | Directory Open Access Journal |
| issn | 2645-4904 |
| language | English |
| last_indexed | 2024-04-13T19:53:51Z |
| publishDate | 2022-06-01 |
| publisher | Shahid Beheshti University of Medical Sciences |
| record_format | Article |
| series | Archives of Academic Emergency Medicine |
| spelling | doaj.art-6bba935b0c48471aa4742517961a3f6f2022-12-22T02:32:26ZengShahid Beheshti University of Medical SciencesArchives of Academic Emergency Medicine2645-49042022-06-0110110.22037/aaem.v10i1.1621Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled TrialRama Bozorgmehr0Farbod AmiriMohammad Hosein ZadeFariba GhorbaniArash Khameneh BagheriEsmat YazdiSayyed Mojtaba NekooghadamGuitti PourdowlatAlireza FatemiClinical research development unit,shohadaye tajrish hospital,shahid beheshti university of medical sciences ,Tehran,Iran Introduction: Efforts to control the COVID-19 pandemic are still on. This study aimed to evaluate the effect of sofosbuvir on length of hospital stay and complications in COVID-19 cases with moderate severity. Methods: This randomized clinical trial was done on moderate COVID-19 cases, who were admitted to Shohadaye Tajrish Hospital, Tehran, Iran, from 4/2021 to 9/2021. Eligible patients were randomly allocated into two groups of intervention (sofosbuvir) and control, and their outcomes were compared regarding the length of hospital stay and complications. Results: 100 COVID-19 cases were randomly divided into two groups of 50 patients, as the intervention and control groups. The mean age of patients was 50.56 ± 12.23 and 57.1±14.1 years in the intervention and control groups, respectively (p = 0.02). The two groups were similar regarding distribution of gender (p = 0.15), underlying diseases (p = 0.08), the severity of COVID-19 (p = 0.80) at the time of admission, signs and symptoms (p > 0.05), and essential laboratory profile (p > 0.05). The length of hospital stay in the control and intervention groups was 7.7 ± 4.09 days and 4.7±1.6 days, respectively (p = 0.02). None of our patients needed ICU or mechanical ventilation. Conclusion: Sofosbuvir may decrease the length of hospital stay of COVID-19 cases with moderate severity, without a significant effect on the rate of intensive care unit (ICU) need and mortality. https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/1621SARS-CoV-2Treatment OutcomeSofosbuvirDuration of Therapy |
| spellingShingle | Rama Bozorgmehr Farbod Amiri Mohammad Hosein Zade Fariba Ghorbani Arash Khameneh Bagheri Esmat Yazdi Sayyed Mojtaba Nekooghadam Guitti Pourdowlat Alireza Fatemi Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial Archives of Academic Emergency Medicine SARS-CoV-2 Treatment Outcome Sofosbuvir Duration of Therapy |
| title | Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial |
| title_full | Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial |
| title_fullStr | Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial |
| title_full_unstemmed | Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial |
| title_short | Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial |
| title_sort | effect of sofosbuvir on length of hospital stay in moderate covid 19 cases a randomized controlled trial |
| topic | SARS-CoV-2 Treatment Outcome Sofosbuvir Duration of Therapy |
| url | https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/1621 |
| work_keys_str_mv | AT ramabozorgmehr effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial AT farbodamiri effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial AT mohammadhoseinzade effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial AT faribaghorbani effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial AT arashkhamenehbagheri effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial AT esmatyazdi effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial AT sayyedmojtabanekooghadam effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial AT guittipourdowlat effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial AT alirezafatemi effectofsofosbuvironlengthofhospitalstayinmoderatecovid19casesarandomizedcontrolledtrial |